NCT07024563 - Study of Ravulizumab in Pediatric Participants With Primary IgAN | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 14, 2025

Primary Completion Date

July 7, 2027

Study Completion Date

November 23, 2028

Conditions

IgANIgAVNImmunoglobulin A NephropathyImmunoglobulin A Vasculitis Associated NephritisHenoch-schonlein Purpura NephritisIgA Vasculitis

Interventions

DRUG

Ravulizumab

Participants will receive Ravulizumab via intravenous (IV) infusion.

Trial Locations (12)

333

RECRUITING

Research Site, Taoyuan District

8950

RECRUITING

Research Site, Barcelona

10002

RECRUITING

Research Site, Taipei

10126

RECRUITING

Research Site, Torino

16147

RECRUITING

Research Site, Genova

41013

RECRUITING

Research Site, Seville

80045

RECRUITING

Research Site, Aurora

100045

NOT_YET_RECRUITING

Research Site, Beijing

201102

NOT_YET_RECRUITING

Research Site, Shanghai

00165

RECRUITING

Research Site, Roma

03080

RECRUITING

Research Site, Seoul

08035

RECRUITING

Research Site, Barcelona